About this course

Risk stratification of HPV-positive cases is changing in response to vaccination and clinical data. In this lecture, Dr Stoler and Dr Wright examine implications of the recent IMPACT trial (N=35,263) on primary HPV screening and triage, respectively. Speakers explain the background behind an updated algorithm using genotyping and dual staining to reduce the number of colposcopies undertaken by concentrating healthcare resources on clinically meaningful HPV-positive cases.

Learning outcomes

• Identify factors necessitating HPV screening of increased sensitivity.
• Compare the risk of cervical disease in people screened HPV-negative or HPV-positive for HPV16/18 and 12 other HPVs.
• Evaluate the performance of dual staining versus cytology in risk stratification of HPV-positive cases.
• Explain the impact of shifting from cytology to dual staining on HPV management algorithms (including sensitivity, residual disease and number of colposcopies).

Topics covered

• Sensitivity of HPV screening required given reduced disease prevalence
• Risk stratification of HPV-positive cases: genotyping and cytology in clinical trials
• Practical guidance for identifying clinically meaningful HPV-positive cases

Additional reading:

• IMPACT trial
• Kaiser study
• Centre for Health Protection – Recommendations on Prevention and Screening for Cervical Cancer (For Health Professionals)
• Department of Health introduced HPV testing for women aged 30–64 years from 3 April 2023

Organised by:

Supported by: